Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Workup and Molecular Testing for a Patient with NSCLC

January 24th 2023

David H. Harpole Jr, MD, a thoracic surgeon, details his workup approach and discussed molecular testing for patients who present with NSCLC.

Navigating Barriers to Molecular Testing and Role of Liquid Biopsy in NSCLC

January 23rd 2023

Expert oncologists discuss barriers to molecular testing and the use of liquid biopsy in non–small cell lung cancer.

The Role of Molecular Testing In Metastatic NSCLC

January 23rd 2023

Martin Dietrich, MD, PhD, and Meghan J. Mooradian, MD, give an overview of the role of molecular biomarkers in the non–small cell lung cancer treatment space.

Dy Discusses CEACAM5-Directed and Other Second-Line Treatment Strategies in NSCLC

January 19th 2023

Dr Dy discusses the development of CEACAM5-directed antibody-drug conjugates in non–small cell lung cancer, ongoing research with tusamitamab ravtansine, and the potential role of competing docetaxel-based combination strategies in the second-line setting.

Perioperative Toripalimab Plus Chemotherapy Meets EFS End Point in NSCLC

January 18th 2023

Perioperative treatment with the combination of toripalimab plus platinum-containing doublet chemotherapy, followed by toripalimab monotherapy as consolidation therapy after surgery, significantly extended event-free survival compared with chemotherapy plus placebo in patients with operable NSCLC.

Patient Profile 1: A 57-Year-Old Woman Diagnosed With NSCLC

January 17th 2023

David Spigel, MD, presents a patient case of a 57-year-old woman with NSCLC, and Jaspal Singh, MD, MHS, discusses his approach to initial evaluation.

Multidisciplinary Care in Non-Small Cell Lung Cancer

January 17th 2023

A panel of experts introduce themselves and explain their approaches to multidisciplinary care in treating non-small cell lung cancer.

FDA Grants Orphan Drug Designation to JBI-802 for Small Cell Lung Cancer and AML

January 16th 2023

The FDA has granted an orphan drug designation to JBI-802 for the treatment of patients with small cell lung cancer and acute myeloid leukemia.

Dr. Mercado on Evolution of Biopsy Techniques in Lung Cancer

January 12th 2023

Jorge M. Mercado, MD, discusses the evolution of biopsy techniques in patients with lung cancer.

Dr. Topp on the Safety Profile of Glofitamab Plus R-CHOP in DLBCL

January 12th 2023

Max S. Topp, MD, discusses the safety profile of glofitamab in combination with R-CHOP in patients with diffuse large B-cell lymphoma.

Spira Highlights Key Advancements Across the NSCLC Treatment Paradigm in 2022

January 11th 2023

Alexander Spira, MD, PhD, FACP, highlights the top advancements across non–small cell lung cancer in 2022, emphasized the need for increased genetic testing to inform treatment decisions, and previewed other agents under development.

Mobocertinib Garners Approval in China for EGFR Exon 20 Insertion+ NSCLC

January 11th 2023

The National Medical Products Administration of China has approved mobocertinib for the treatment of adult patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations and whose disease progressed on or following platinum-based chemotherapy.

CTLA-4–Based Combinations Highlight Evolution of Treatment in Metastatic NSCLC

January 11th 2023

Vamsidhar Velcheti, MD, highlights the advancement of CTLA-4–based combinations in non–small cell lung cancer treatment, the emergence of antibody-drug conjugates in non–small cell lung cancer, and the impact of the POSEIDON trial on the treatment landscape.

IBI351 Gets Breakthrough Therapy Designation for KRAS G12C–Mutated NSCLC in China

January 10th 2023

The Center for Drug Evaluation of China's National Medical Products Administration has granted a breakthrough therapy designation to IBI351 for the treatment of patients with advanced non–small cell lung cancer harboring a KRAS G12C mutation who have received at least 1 prior line of systemic therapy.

Neoadjuvant SHR-1701 Increases Response, Resectability in Stage III Unresectable NSCLC

January 8th 2023

Neoadjuvant treatment with SHR-1701 with or without chemotherapy followed by surgery or radiotherapy induced responses in more than half of patients with stage III unresectable non–small cell lung cancer and increased resectability in those assigned to definitive surgery.

Abequolixron Plus Docetaxel Elicits Responses in Relapsed/Refractory Lung Cancer

January 6th 2023

The addition of abequolixron to docetaxel generated responses in patients with relapsed/refractory non–small cell lung cancer or small cell lung cancer.

Japan Approves Durvalumab/Tremelimumab Combo for HCC and Advanced NSCLC

January 6th 2023

Japan has approved durvalumab monotherapy and durvalumab plus tremelimumab for unresectable hepatocellular carcinoma, durvalumab plus tremelimumab and chemotherapy for unresectable, advanced, or recurrent non–small cell lung cancer, and durvalumab plus chemotherapy for curatively unresectable biliary tract cancer.

FDA Approves FoundationOne Liquid CDx as a Companion Diagnostic for Entrectinib

January 5th 2023

The FDA has approved FoundationOne Liquid CDx as a companion diagnostic for use with the selective TKI entrectinib. The assay identifies patients with ROS1-positive NSCLC or NTRK fusion–positive solid tumors who do not have a tissue sample available and who may be appropriate for entrectinib treatment.

TTFields Plus SOC Meets Primary End Point in Stage IV NSCLC After Failure of Platinum-Based Chemotherapy

January 5th 2023

Tumor treating fields plus standard-of-care therapies led to a statistically significant and clinically meaningful improvement in overall survival vs SOC alone in patients with stage IV NSCLC who progressed while on or after platinum chemotherapy, meeting the primary end point of the LUNAR trial.

FDA Grants Breakthrough Device Designation to OverC Multi-Cancer Detection Blood Test

January 4th 2023

The FDA has granted a breakthrough device designation to the OverC Multi-Cancer Detection Blood Test for the early detection of cancers including esophageal, liver, lung, ovarian, and pancreatic in adults aged to 50 to 75 years with average risk.